Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Exela Pharma Sciences LLC
EIR
•Exela Pharma Sciences LLC•October 22, 2019

Exela Pharma Sciences LLC – FDA EIR, Oct 22, 2019

Record Details

An FDA pre-approval inspection of Exela Pharma Sciences LLC in Lenoir, NC, was conducted from October 15-22, 2019, under Compliance Program 7346.832. The inspection aimed to assess readiness for commercial manufacturing of several sterile small volume parenteral and terminally sterilized drug products, particularly at their new Augusta manufacturing site. This inspection also followed up on a previous March 2019 inspection that resulted in a ten-item FDA 483. Previous violations included issues with data integrity for laboratory controls and critical equipment, inadequate environmental monitoring, use of non-cleanable equipment, deficiencies in batch records, material control, storage, facility space, equipment logs, and employee training. During the October 2019 inspection, Exela Pharma Sciences demonstrated that many corrections to the prior 483 observations were implemented and verified. Consequently, no new FDA Form 483, Inspectional Observations, was issued. However, the inspection concluded with five verbal observations requiring action. These included concerns regarding unpaginated batch record review forms, cleaning residue on manufacturing equipment at the Augusta facility, the need for more scientifically sound cleaning validation calculations for new product introductions, inconsistent operation and lack of qualification details for warehouse ceiling fans, and an unsealed opening observed in a Michelle facility filling operation. The company acknowledged these observations and committed to implementing corrective actions. They also confirmed ongoing efforts, supported by external consultants, to address previous findings and enhance manufacturing capabilities.

Company
Exela Pharma Sciences LLC
Inspection date
October 22, 2019
Product type
drugs
Office
Atlanta District Office
People
  • Baron Bowers (company_representative)
  • Adam R. Cooke (Commissioned Corps of the U.S. Public Health Service)
  • Gary J. Brennan (recipient)
  • Doug Schmidt (company_representative)
  • Cassandra L. Abellard (investigator)
View Company Profile

ID · 1ff0bf60-f6da-4f02-ac0b-9fa76949550e

Violation Codes1
21 CFR 211

Full citation text and observation details available on the Dashboard.

Other documents for Exela Pharma Sciences LLC
  • WARNING_LETTER - 2024-11-15November 15, 2024
  • 483 - 2024-11-04November 4, 2024
  • EIR - 2019-07-18July 18, 2019
  • 483 - 2019-07-18July 18, 2019
  • WARNING_LETTER - 2019-07-18July 18, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Exela Pharma Sciences LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.